David Woods

2.5k citations

42 papers · 1.6k indexed · h-index 17

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in

Oncology 24
- Cancer Immunotherapy and Biomarkers 14
- CAR-T cell therapy research 12
- Peptidase Inhibition and Analysis 6
Immunology 14
- Immunotherapy and Immune Responses 9
- Immune Cell Function and Interaction 4

Co-authors: Jeffrey S. Weber Eduardo M. Sotomayor Alejandro Villagra Andressa L. Sodré Amod A. Sarnaik Andressa S. Laino Melinda Vassallo Karrune Woan
Journals: Cancer Immunology Research (5 papers)Cancer Research (5 papers)Blood (5 papers)The Journal of Immunology (4 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States Australia United Kingdom

In The Last Decade

David Woods

41 papers receiving 1.6k citations

Peers

Countries citing papers authored by David Woods

Since Specialization

Citations

This map shows the geographic impact of David Woods's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Woods with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Woods more than expected).

Fields of papers citing papers by David Woods

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Woods. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Woods. The network helps show where David Woods may publish in the future.

Co-authors

The 25 scholars most cited alongside David Woods, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Woods Line = papers co-authored together David Woods links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Clinical Cancer Research ·Erkki Valta, Brian Thompson, 駿秋山, Carol M. Amato, Melinda Vassallo, Igor Dolgalev, 菊川清見, 공성윤, Diana Kimono, Amrutesh S. Puranik, Jeffrey S. Weber, David Woods	2023	9
2	CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy The Journal of Immunology ·Brian Thompson, 駿秋山, Carol M. Amato, 菊川清見, Amod A. Sarnaik, Jeffrey S. Weber, David Woods	2023	2
3	Risk factors for screw breach and iatrogenic nerve injury in percutaneous posterior pelvic ring fixation Journal of Clinical Orthopaedics and Trauma ·Michael M. Hadeed, David Woods, 惇池上, K. Thirumalai, Cyril Mauffrey, Joshua A. Parry	2022	13
4	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells Clinical Cancer Research ·Junya Ichikawa, Tatsuya Yoshida, Ariel Isser, Andressa S. Laino, Melinda Vassallo, David Woods, Sojung Kim, Mathias Oelke, Kristi Jones, Jonathan P. Schneck, Jeffrey S. Weber	2020	34
5	Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition Journal for ImmunoTherapy of Cancer ·Andressa S. Laino, David Woods, Melinda Vassallo, Xiaozhong Qian, Hao Tang, Megan Wind‐Rotolo, Jeffrey S. Weber	2020	166
6	C reactive protein impairs adaptive immunity in immune cells of patients with melanoma Journal for ImmunoTherapy of Cancer ·Tatsuya Yoshida, Junya Ichikawa, J. Bens, Andressa S. Laino, Yuhan Hao, Michelle Krogsgaard, Melinda Vassallo, David Woods, F. Stephen Hodi, Jeffrey S. Weber	2020	65
7	Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes JCI Insight ·David Woods, Andressa S. Laino, Aidan Winters, K Padmanabhan, Dan Freeman, Vinay Rao, Zanele Heavy-Girl Dube-Xaba, Jeffrey S. Weber, Pratip K. Chattopadhyay	2020	15
8	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma Cancer Immunology Research ·Erik Yusko, Marissa Vignali, Richard K. Wilson, Elaine R. Mardis, F. Stephen Hodi, Christine E. Horak, Han Chang, David Woods, Harlan Robins, Jeffrey S. Weber	2019	38
9	HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics Journal for ImmunoTherapy of Cancer ·Andressa S. Laino, Brian C. Betts, Anandharaman Veerapathran, Igor Dolgalev, Amod A. Sarnaik, Steven N. Quayle, Simon S. Jones, Jeffrey S. Weber, David Woods	2019	66
10	Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma Clinical Cancer Research ·David Woods, Rupal Ramakrishnan, Andressa S. Laino, Anders Berglund, Kelly Walton, Brian C. Betts, Jeffrey S. Weber	2018	50
11	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy Cancer Immunology Immunotherapy ·David M. Briere, Niranjan Sudhakar, David Woods, Jill Hallin, Lars D. Engstrom, Ruth Aranda, Harrah Chiang, Andressa L. Sodré, Peter Olson, Jeffrey S. Weber, James G. Christensen	2017	117
12	Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab Annals of Oncology ·Jeffrey S. Weber, Christine E. Horak, F. Stephen Hodi, Han Chang, David Woods, Catherine Sanders, Harlan Robins, Erik Yusko	2016	9
13	In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties. Journal of Clinical Oncology ·Fengdong Cheng, Andressa S. Laino, Hongwei Wang, Jie Chen, О. М. Кошовий, David Woods, Jeffrey S. Weber, Steven N. Quayle, Simon S. Jones, Eduardo M. Sotomayor	2016	1
14	Abstract A074: Selective Inhibition of HDAC6 augments T-cell central memory and enhances anti-tumor functions: Implications in TIL therapy Cancer Immunology Research ·Andressa S. Laino, David Woods, Amod A. Sarnaik, Jeffrey S. Weber, Eduardo M. Sotomayor	2016	1
15	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Cancer Immunology Research ·David Woods, Andressa L. Sodré, Alejandro Villagra, Amod A. Sarnaik, Eduardo M. Sotomayor, Jeffrey S. Weber	2015	348
16	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function Molecular Immunology ·Eva Sahakian, John J. Powers, Jie Chen, Susan Deng, Fengdong Cheng, Allison Distler, David Woods, Jennifer Rock-Klotz, Andressa L. Sodré, Je-In Youn, Karrune Woan, Alejandro Villagra, Dmitry I. Gabrilovich, Eduardo M. Sotomayor, Javier Pinilla‐Ibarz	2014	96
17	Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells Molecular Immunology ·Fengdong Cheng, Maritza Lienlaf, Patricio Perez-Villarroel, Hongwei Wang, Calvin Lee, Karrune Woan, David Woods, Tessa Knox, Joel Bergman, Javier Pinilla‐Ibarz, Alan P. Kozikowski, Edward Seto, Eduardo M. Sotomayor, Alejandro Villagra	2014	113
18	The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity Melanoma Research ·David Woods, Karrune Woan, Fengdong Cheng, Hongwei Wang, Patricio Perez-Villarroel, Calvin Lee, Maritza Lienlaf, Peter Atadja, Edward Seto, Jeffrey S. Weber, Eduardo M. Sotomayor, Alejandro Villagra	2013	81
19	QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION SHILAP Revista de lepidopterología ·Alhossain A. Khalafallah, Dunford E.K, Isabella Hoang, Iain Robertson, David Woods	2011	9
20	Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom Toxicon ·Geoffrey K. Isbister, David Woods, Manuela Molina Salmerón, Margaret A. O’Leary, Michael Seldon, Lisa F. Lincz	2010	35

About David Woods

David Woods is a scholar working on Oncology, Immunology, Molecular Biology, Hematology and Cancer Research, having authored 42 papers that have together received 1.6k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (22 papers), Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (12 papers), Protein Degradation and Inhibitors (11 papers), Immunotherapy and Immune Responses (9 papers), Peptidase Inhibition and Analysis (6 papers), Epigenetics and DNA Methylation (5 papers) and Immune Cell Function and Interaction (4 papers). The work is most often cited by research in Oncology (877 citations), Immunology (587 citations), Molecular Biology (890 citations), Virology (49 citations) and Cancer Research (94 citations). David Woods has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Jeffrey S. Weber, Eduardo M. Sotomayor, Alejandro Villagra, Andressa L. Sodré, Amod A. Sarnaik, Andressa S. Laino, Melinda Vassallo, Karrune Woan, Fengdong Cheng and Megan Wind‐Rotolo. Their work appears in journals such as Cancer Immunology Research, Cancer Research, Blood, The Journal of Immunology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact